Compound ID,Uniprot,Target,E3 ligase,PDB,Name,Smiles,DC50 (nM),Dmax (%),Assay (DC50/Dmax),Percent degradation (%),Assay (Percent degradation),"IC50 (nM, Protac to Target)","Assay (Protac to Target, IC50)","EC50 (nM, Protac to Target)","Assay (Protac to Target, EC50)","Kd (nM, Protac to Target)","Assay (Protac to Target, Kd)","Ki (nM, Protac to Target)","Assay (Protac to Target, Ki)","delta G (kcal/mol, Protac to Target)","delta H (kcal/mol, Protac to Target)","-T*delta S (kcal/mol, Protac to Target)","Assay (Protac to Target, G/H/-TS)","kon (1/Ms, Protac to Target)","koff (1/s, Protac to Target)","t1/2 (s, Protac to Target)","Assay (Protac to Target, kon/koff/t1/2)","IC50 (nM, Protac to E3)","Assay (Protac to E3, IC50)","EC50 (nM, Protac to E3)","Assay (Protac to E3, EC50)","Kd (nM, Protac to E3)","Assay (Protac to E3, Kd)","Ki (nM, Protac to E3)","Assay (Protac to E3, Ki)","delta G (kcal/mol, Protac to E3)","delta H (kcal/mol, Protac to E3)","-T*delta S (kcal/mol, Protac to E3)","Assay (Protac to E3, G/H/-TS)","kon (1/Ms, Protac to E3)","koff (1/s, Protac to E3)","t1/2 (s, Protac to E3)","Assay (Protac to E3, kon/koff/t1/2)","IC50 (nM, Ternary complex)","Assay (Ternary complex, IC50)","EC50 (nM, Ternary complex)","Assay (Ternary complex, EC50)","Kd (nM, Ternary complex)","Assay (Ternary complex, Kd)","Ki (nM, Ternary complex)","Assay (Ternary complex, Ki)","delta G (kcal/mol, Ternary complex)","delta H (kcal/mol, Ternary complex)","-T*delta S (kcal/mol, Ternary complex)","Assay (Ternary complex, G/H/-TS)","kon (1/Ms, Ternary complex)","koff (1/s, Ternary complex)","t1/2 (s, Ternary complex)","Assay (Ternary complex, kon/koff/t1/2)","IC50 (nM, Cellular activities)","Assay (Cellular activities, IC50)","EC50 (nM, Cellular activities)","Assay (Cellular activities, EC50)","GI50 (nM, Cellular activities)","Assay (Cellular activities, GI50)","ED50 (nM, Cellular activities)","Assay (Cellular activities, ED50)","GR50 (nM, Cellular activities)","Assay (Cellular activities, GR50)","PAMPA Papp (nm/s, Permeability)","Assay (Permeability, PAMPA Papp)","Caco-2 A2B Papp (nm/s, Permeability)","Assay (Permeability, Caco-2 A2B Papp)","Caco-2 B2A Papp (nm/s, Permeability)","Assay (Permeability, Caco-2 B2A Papp)",Article DOI,Molecular Weight,Exact Mass,XLogP3,Heavy Atom Count,Ring Count,Hydrogen Bond Acceptor Count,Hydrogen Bond Donor Count,Rotatable Bond Count,Topological Polar Surface Area,Molecular Formula,InChI,InChI Key
256,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCCOC3=CC=C(N4C(=S)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,15,76,Degradation of AR in VCaP cells after 20 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,<1,Compounds were administered at 10000 nM and incubated for 5 h,0.35,Compounds were administered at 10000 nM and incubated for 2 h,0.24,Compounds were administered at 10000 nM and incubated for 2 h,10.1038/s42003-018-0105-8; 10.1021/acsmedchemlett.0c00194,1020.21,1019.38968854,7.45,71,6,12,3,21,186.66,C51H60F3N7O8S2,"InChI=1S/C51H60F3N7O8S2/c1-32-43(71-31-57-32)34-13-11-33(12-14-34)28-56-45(64)41-26-38(62)29-59(41)46(65)44(49(2,3)4)58-42(63)30-68-23-10-22-67-21-8-7-9-24-69-39-19-17-36(18-20-39)61-48(70)60(47(66)50(61,5)6)37-16-15-35(27-55)40(25-37)51(52,53)54/h11-20,25,31,38,41,44,62H,7-10,21-24,26,28-30H2,1-6H3,(H,56,64)(H,58,63)/t38-,41+,44-/m1/s1",MTZBLTXMAXNSIO-UMWCMSNQSA-N
330,O60885,BRD4,CRBN,,dBET1,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCCCCNC(=O)COC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1=CC=C(Cl)C=C1,5.27/2.9,,Degradation of BRD4 in MV4-11 cells after 12/24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11.6,Compounds were administered at 10000 nM and incubated for 2 h,,,10.1002/anie.202108848,785.283,784.219444204,3.22,55,7,12,3,12,194.05,C38H37ClN8O7S,"InChI=1S/C38H37ClN8O7S/c1-19-20(2)55-38-31(19)33(22-9-11-23(39)12-10-22)42-25(34-45-44-21(3)46(34)38)17-29(49)40-15-4-5-16-41-30(50)18-54-27-8-6-7-24-32(27)37(53)47(36(24)52)26-13-14-28(48)43-35(26)51/h6-12,25-26H,4-5,13-18H2,1-3H3,(H,40,49)(H,41,50)(H,43,48,51)/t25-,26?/m0/s1",LKEGXJXRNBALBV-PMCHYTPCSA-N
335,O60885,BRD4,VHL,,MZ1,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C[C@@H]3N=C(C4=CC=C(Cl)C=C4)C4=C(SC(C)=C4C)N4C(C)=NN=C34)C(C)(C)C)C=C2)SC=N1,250,100,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,95,ITC,,,,,,,,,,,,,,,,,,,,,,,0.11,Caco-2 A2B assay,9,Caco-2 B2A assay,10.1002/cmdc.202200615,1002.661,1001.36947956,4.96,69,7,15,4,20,211.49,C49H60ClN9O8S2,"InChI=1S/C49H60ClN9O8S2/c1-28-30(3)69-48-41(28)42(33-12-14-35(50)15-13-33)54-37(45-57-56-31(4)59(45)48)23-39(61)51-16-17-65-18-19-66-20-21-67-26-40(62)55-44(49(5,6)7)47(64)58-25-36(60)22-38(58)46(63)52-24-32-8-10-34(11-9-32)43-29(2)53-27-68-43/h8-15,27,36-38,44,60H,16-26H2,1-7H3,(H,51,61)(H,52,63)(H,55,62)/t36-,37+,38+,44-/m1/s1",PTAMRJLIOCHJMQ-PYNGZGNASA-N
466,,BCR-ABL,VHL,,SIAIS178,CC1=NC(NC2=NC=C(C(=O)NC3=C(C)C=CC=C3Cl)S2)=CC(N2CCN(C(=O)CCCCCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)CC2)=N1,8.5,,Degradation of BCR-ABL in K562 cells after 16 h treatment,,,,,,,0.35/0.14,Kd of non-phosphorylated/phosphorylated c-ABL was tested using the KinomeScan platform,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,24,Inhibit growth of K562 cells,,,,,,,,,,,0.02,Compounds were administered at 10000 nM and incubated for 2 h,0.07,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acs.jmedchem.9b01264,1012.704,1011.40144838,7.48,70,7,14,5,18,214.98,C50H62ClN11O6S2,"InChI=1S/C50H62ClN11O6S2/c1-30-12-11-13-36(51)43(30)59-47(67)38-27-53-49(70-38)57-39-25-40(56-32(3)55-39)60-20-22-61(23-21-60)42(65)15-10-8-7-9-14-41(64)58-45(50(4,5)6)48(68)62-28-35(63)24-37(62)46(66)52-26-33-16-18-34(19-17-33)44-31(2)54-29-69-44/h11-13,16-19,25,27,29,35,37,45,63H,7-10,14-15,20-24,26,28H2,1-6H3,(H,52,66)(H,58,64)(H,59,67)(H,53,55,56,57)/t35-,37+,45-/m1/s1",YGQREOJIRFCRKQ-ZIBKGDFVSA-N
1560,P10275,AR,CRBN,,,CC1(C)C(=O)N(C2=CC=C(C#N)C(C(F)(F)F)=C2)C(=S)N1C1=CC=C(OCCOCCOCCOCCOC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)C=C1,,N.D.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,<1,Compounds were administered at 10000 nM and incubated for 5 h,1.7,Compounds were administered at 10000 nM and incubated for 2 h,14.1,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acsmedchemlett.0c00194,837.83,837.229148076,3.63,59,6,12,1,17,177.04,C40H38F3N5O10S,"InChI=1S/C40H38F3N5O10S/c1-39(2)37(53)46(26-7-6-24(23-44)29(22-26)40(41,42)43)38(59)48(39)25-8-10-27(11-9-25)57-20-18-55-16-14-54-15-17-56-19-21-58-31-5-3-4-28-33(31)36(52)47(35(28)51)30-12-13-32(49)45-34(30)50/h3-11,22,30H,12-21H2,1-2H3,(H,45,49,50)",AWZDAIQLULBEES-UHFFFAOYSA-N
1562,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCCCCOC3=CC=C(N4C(=S)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,,,,,,25,IC50 was assessed using a radio-ligand displacement assay,,,,,11,Ki was assessed using a radio-ligand displacement assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,<1,Compounds were administered at 10000 nM and incubated for 5 h,<2.7,Compounds were administered at 10000 nM and incubated for 2 h,1.4,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acsmedchemlett.0c00194,1006.183,1005.37403848,7.09,70,6,12,3,20,186.66,C50H58F3N7O8S2,"InChI=1S/C50H58F3N7O8S2/c1-31-42(70-30-56-31)33-12-10-32(11-13-33)27-55-44(63)40-25-37(61)28-58(40)45(64)43(48(2,3)4)57-41(62)29-67-22-9-21-66-20-7-8-23-68-38-18-16-35(17-19-38)60-47(69)59(46(65)49(60,5)6)36-15-14-34(26-54)39(24-36)50(51,52)53/h10-19,24,30,37,40,43,61H,7-9,20-23,25,27-29H2,1-6H3,(H,55,63)(H,57,62)/t37-,40+,43-/m1/s1",UYAKVNKOLXEIRY-AKCINUCUSA-N
1563,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCC(F)(F)C(F)(F)C(F)(F)COCCCOC3=CC=C(N4C(=S)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,<1,Compounds were administered at 10000 nM and incubated for 5 h,0.26,Compounds were administered at 10000 nM and incubated for 2 h,<0.79,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acsmedchemlett.0c00194,1128.15,1127.33315767,8.39,77,6,12,3,21,186.66,C51H54F9N7O8S2,"InChI=1S/C51H54F9N7O8S2/c1-29-40(77-28-63-29)31-10-8-30(9-11-31)23-62-42(70)38-21-35(68)24-65(38)43(71)41(46(2,3)4)64-39(69)25-74-27-49(54,55)51(59,60)48(52,53)26-73-18-7-19-75-36-16-14-33(15-17-36)67-45(76)66(44(72)47(67,5)6)34-13-12-32(22-61)37(20-34)50(56,57)58/h8-17,20,28,35,38,41,68H,7,18-19,21,23-27H2,1-6H3,(H,62,70)(H,64,69)/t35-,38+,41-/m1/s1",YQJIYEVGJLJDLM-LFHXYJAASA-N
1564,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCOCCOCCOCCOC3=CC=C(N4C(=S)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,<1,Compounds were administered at 10000 nM and incubated for 5 h,<0.69,Compounds were administered at 10000 nM and incubated for 2 h,8.6,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acsmedchemlett.0c00194,1022.182,1021.3689531,5.77,71,6,13,3,21,195.89,C50H58F3N7O9S2,"InChI=1S/C50H58F3N7O9S2/c1-31-42(71-30-56-31)33-9-7-32(8-10-33)28-55-44(63)40-26-37(61)29-58(40)45(64)43(48(2,3)4)57-41(62)17-18-66-19-20-67-21-22-68-23-24-69-38-15-13-35(14-16-38)60-47(70)59(46(65)49(60,5)6)36-12-11-34(27-54)39(25-36)50(51,52)53/h7-16,25,30,37,40,43,61H,17-24,26,28-29H2,1-6H3,(H,55,63)(H,57,62)/t37-,40+,43-/m1/s1",AHPZKNARQBAMMU-AKCINUCUSA-N
1567,P10275,AR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCCOCC(F)(F)C(F)(F)COC3=CC=C(N4C(=S)N(C5=CC=C(C#N)C(C(F)(F)F)=C5)C(=O)C4(C)C)C=C3)C(C)(C)C)C=C2)SC=N1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,<1,Compounds were administered at 10000 nM and incubated for 5 h,<0.11,Compounds were administered at 10000 nM and incubated for 2 h,0.33,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acsmedchemlett.0c00194,1078.143,1077.33635123,7.72,74,6,12,3,20,186.66,C50H54F7N7O8S2,"InChI=1S/C50H54F7N7O8S2/c1-29-40(74-28-60-29)31-10-8-30(9-11-31)23-59-42(67)38-21-35(65)24-62(38)43(68)41(46(2,3)4)61-39(66)25-70-18-7-19-71-26-48(51,52)49(53,54)27-72-36-16-14-33(15-17-36)64-45(73)63(44(69)47(64,5)6)34-13-12-32(22-58)37(20-34)50(55,56)57/h8-17,20,28,35,38,41,65H,7,18-19,21,23-27H2,1-6H3,(H,59,67)(H,61,66)/t35-,38+,41-/m1/s1",DRPPHAFHVRTMSO-LFHXYJAASA-N
1598,O43924,PDEdelta,CRBN,,,CC1=CC=C(N2N=C3C(=O)N(CCCC(=O)NCCCCCCCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)N=C(C)C3=C2C)C=C1,3600,,Degradation of PDEdelta in SW480 cells after 24 h treatment,,,,,,,9,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8000/8000,Inhibit growth of SW480/HCT116 cells,,,,,,,,,,,0.37,Compounds were administered at 10000 nM and incubated for 2 h,12.84,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acs.jmedchem.0c00929,722.847,722.354031192,4.82,53,6,11,3,16,177.39,C39H46N8O6,"InChI=1S/C39H46N8O6/c1-24-15-17-27(18-16-24)47-26(3)33-25(2)43-45(39(53)35(33)44-47)23-11-14-31(48)41-22-9-7-5-4-6-8-21-40-29-13-10-12-28-34(29)38(52)46(37(28)51)30-19-20-32(49)42-36(30)50/h10,12-13,15-18,30,40H,4-9,11,14,19-23H2,1-3H3,(H,41,48)(H,42,49,50)",UETAXZPCBATLJC-UHFFFAOYSA-N
1655,Q05397,FAK,CRBN,,BI-3663,COC1=CC(C(=O)NCCOCCOCCOCCC(=O)NC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,158/50/13,79/93/93,Degradation of Fak in HLE/HuH-7/SNU-423 cells after 18 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,>25119/>25119/19953,Inhibit proliferation of HLE/HuH-7/SNU-423 cells,,,,,,,,,,,1,Compounds were administered at 10000 nM and incubated for 2 h,17,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acs.jmedchem.8b01826,917.851,917.284354444,2.93,66,7,15,4,20,242.78,C44H42F3N7O12,"InChI=1S/C44H42F3N7O12/c1-62-33-22-25(8-10-28(33)51-43-49-23-27(44(45,46)47)40(53-43)66-32-7-2-4-24-9-12-31(55)36(24)32)38(58)48-15-17-64-19-21-65-20-18-63-16-14-35(57)50-29-6-3-5-26-37(29)42(61)54(41(26)60)30-11-13-34(56)52-39(30)59/h2-8,10,22-23,30H,9,11-21H2,1H3,(H,48,58)(H,50,57)(H,49,51,53)(H,52,56,59)",ADTXLFJKQHYGPM-UHFFFAOYSA-N
1656,Q05397,FAK,VHL,,BI-0319,COC1=CC(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC2=CC=C(C3=C(C)N=CS3)C=C2)C(C)(C)C)=CC=C1NC1=NC=C(C(F)(F)F)C(OC2=CC=CC3=C2C(=O)CC3)=N1,243/631/32,80/59/98,Degradation of Fak in A549/Hep3B2.1-7/SNU-387 cells after 18 h treatment,,,19,Inhibition of Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5012/6310,Inhibit proliferation of SNU-387/Hep3B2.1-7 cells,,,,,,,,,,,<1,Compounds were administered at 10000 nM and incubated for 2 h,11,Compounds were administered at 10000 nM and incubated for 2 h,10.1021/acs.jmedchem.8b01826,1061.15,1060.39761037,5.49,75,7,16,5,23,241.76,C52H59F3N8O11S,"InChI=1S/C52H59F3N8O11S/c1-30-44(75-29-59-30)33-11-9-31(10-12-33)25-57-47(68)38-24-35(64)27-63(38)49(69)45(51(2,3)4)61-42(66)28-73-22-21-72-20-19-71-18-17-56-46(67)34-13-15-37(41(23-34)70-5)60-50-58-26-36(52(53,54)55)48(62-50)74-40-8-6-7-32-14-16-39(65)43(32)40/h6-13,15,23,26,29,35,38,45,64H,14,16-22,24-25,27-28H2,1-5H3,(H,56,67)(H,57,68)(H,61,66)(H,58,60,62)/t35-,38+,45-/m1/s1",UVVQLQQNGHYTOL-JIVXZRRKSA-N
2449,Q15910,EZH2,VHL,,YM281,CCN(C1=CC(C2=CC=C(OCCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)C=C2)=CC(C(=O)NCC2=C(C)C=C(C)[NH]C2=O)=C1C)C1CCOCC1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.025,Caco-2 A2B assay,,,10.1021/acs.jmedchem.1c00460,1018.291,1017.50339785,7.01,73,7,12,5,20,204.52,C56H71N7O9S,"InChI=1S/C56H71N7O9S/c1-9-62(42-19-23-70-24-20-42)47-27-41(26-45(36(47)4)52(66)58-30-46-34(2)25-35(3)60-53(46)67)39-15-17-44(18-16-39)72-22-10-21-71-32-49(65)61-51(56(6,7)8)55(69)63-31-43(64)28-48(63)54(68)57-29-38-11-13-40(14-12-38)50-37(5)59-33-73-50/h11-18,25-27,33,42-43,48,51,64H,9-10,19-24,28-32H2,1-8H3,(H,57,68)(H,58,66)(H,60,67)(H,61,65)/t43-,48+,51-/m1/s1",HBGYJNIDFUPUJQ-DDGSYWGGSA-N
2450,Q15910,EZH2,VHL,,YM181,CCN(C1=CC(C2=CC=C(OCCOCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C4=C(C)N=CS4)C=C3)C(C)(C)C)C=C2)=CC(C(=O)NCC2=C(C)C=C(C)[NH]C2=O)=C1C)C1CCOCC1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.043,Caco-2 A2B assay,,,10.1021/acs.jmedchem.1c00460,1048.317,1047.51396254,6.51,75,7,13,5,22,213.75,C57H73N7O10S,"InChI=1S/C57H73N7O10S/c1-9-63(43-18-20-71-21-19-43)48-28-42(27-46(37(48)4)53(67)59-31-47-35(2)26-36(3)61-54(47)68)40-14-16-45(17-15-40)74-25-24-72-22-23-73-33-50(66)62-52(57(6,7)8)56(70)64-32-44(65)29-49(64)55(69)58-30-39-10-12-41(13-11-39)51-38(5)60-34-75-51/h10-17,26-28,34,43-44,49,52,65H,9,18-25,29-33H2,1-8H3,(H,58,69)(H,59,67)(H,61,68)(H,62,66)/t44-,49+,52-/m1/s1",DODCRKMIDHTGAE-RMIMYVLFSA-N
2842,Q06187,BTK,CRBN,,,O=C1CCC(N2C(=O)C3=CC=CC(NCCOCCOCCOCCOCCOCCNC(=O)N[C@H]4CC[C@@H](NC5=NC=NC6=C5C(C(=O)C5=CC=C(OC7=CC=CC=C7)C=C5Cl)=C[NH]6)CC4)=C3C2=O)C(=O)N1,41.9,93,Degradation of BTK in JeKo-1 cells after 24 h treatment,,,56.4,Inhibition of BTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45.7,Inhibit proliferation of TMD8 cells,,,,,,,,,,,<0.53,Caco-2 A2B assay,7.5,Caco-2 B2A assay,10.1016/j.ejmech.2021.113820,1024.529,1023.38934598,4.65,73,8,16,6,27,262.76,C51H58ClN9O12,"InChI=1S/C51H58ClN9O12/c52-39-29-35(73-34-5-2-1-3-6-34)13-14-36(39)45(63)38-30-55-46-44(38)47(57-31-56-46)58-32-9-11-33(12-10-32)59-51(67)54-18-20-69-22-24-71-26-28-72-27-25-70-23-21-68-19-17-53-40-8-4-7-37-43(40)50(66)61(49(37)65)41-15-16-42(62)60-48(41)64/h1-8,13-14,29-33,41,53H,9-12,15-28H2,(H2,54,59,67)(H,60,62,64)(H2,55,56,57,58)/t32-,33+,41?",OIAOFDRZXBDDRR-HYKUANOISA-N
2893,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCC1=CN(CCCCNC(=O)COC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)N=N1)N=C2C1=CC=C(Cl)C=C1,,,,,,23.7,IC50 of BRD4 BD2 was assessed by TR-FRET,,,,,,,,,,,,,,,17,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.222/710.45,Inhibit proliferation of MV4-11/HD-MB03 cells,,,,,,,,,,,17,Compounds were administered at 10000 nM and incubated for 2 h,,,10.1002/anie.202108848,866.361,865.2521413,2.45,61,8,15,3,14,224.76,C41H40ClN11O7S,"InChI=1S/C41H40ClN11O7S/c1-21-22(2)61-41-34(21)36(24-9-11-25(42)12-10-24)45-28(37-49-47-23(3)52(37)41)17-32(55)44-18-26-19-51(50-48-26)16-5-4-15-43-33(56)20-60-30-8-6-7-27-35(30)40(59)53(39(27)58)29-13-14-31(54)46-38(29)57/h6-12,19,28-29H,4-5,13-18,20H2,1-3H3,(H,43,56)(H,44,55)(H,46,54,57)/t28-,29?/m0/s1",DCJYEKOZHBUGTG-XLTVJXRZSA-N
2894,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCC1=CN(CCCCNC(=O)CNC3=CC=CC4=C3C(=O)N(C3CCC(=O)NC3=O)C4=O)N=N1)N=C2C1=CC=C(Cl)C=C1,,,,,,1.7,IC50 of BRD4 BD2 was assessed by TR-FRET,,,,,,,,,,,,,,,4,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.208/105,Inhibit proliferation of MV4-11/HD-MB03 cells,,,,,,,,,,,2.2,Compounds were administered at 10000 nM and incubated for 2 h,,,10.1002/anie.202108848,865.377,864.268125712,3.02,61,8,15,4,14,227.56,C41H41ClN12O6S,"InChI=1S/C41H41ClN12O6S/c1-21-22(2)61-41-34(21)36(24-9-11-25(42)12-10-24)46-29(37-50-48-23(3)53(37)41)17-32(56)45-18-26-20-52(51-49-26)16-5-4-15-43-33(57)19-44-28-8-6-7-27-35(28)40(60)54(39(27)59)30-13-14-31(55)47-38(30)58/h6-12,20,29-30,44H,4-5,13-19H2,1-3H3,(H,43,57)(H,45,56)(H,47,55,58)/t29-,30?/m0/s1",RXKCXGDDGPGXLS-UFXYQILXSA-N
2895,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCC1=CN(CCCCNC(=O)COC3=CC=C(C4CCC(=O)NC4=O)C=C3)N=N1)N=C2C1=CC=C(Cl)C=C1,,,,,,1046,IC50 of BRD4 BD2 was assessed by TR-FRET,,,,,,,,,,,,,,,36,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.199/334.55,Inhibit proliferation of MV4-11/HD-MB03 cells,,,,,,,,,,,21.4,Compounds were administered at 10000 nM and incubated for 2 h,,,10.1002/anie.202108848,797.342,796.267063092,3.34,56,7,13,3,14,187.38,C39H41ClN10O5S,"InChI=1S/C39H41ClN10O5S/c1-22-23(2)56-39-35(22)36(26-6-10-27(40)11-7-26)43-31(37-47-45-24(3)50(37)39)18-33(52)42-19-28-20-49(48-46-28)17-5-4-16-41-34(53)21-55-29-12-8-25(9-13-29)30-14-15-32(51)44-38(30)54/h6-13,20,30-31H,4-5,14-19,21H2,1-3H3,(H,41,53)(H,42,52)(H,44,51,54)/t30?,31-/m0/s1",IWOYRWZKNMTQQZ-FLDQDSGZSA-N
2896,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCC1=CN(CCCCNC(=O)CNC3=CC=C(C4CCC(=O)NC4=O)C=C3)N=N1)N=C2C1=CC=C(Cl)C=C1,,,,,,47.9,IC50 of BRD4 BD2 was assessed by TR-FRET,,,,,,,,,,,,,,,92,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.133/102.78,Inhibit proliferation of MV4-11/HD-MB03 cells,,,,,,,,,,,3.2,Compounds were administered at 10000 nM and incubated for 2 h,,,10.1002/anie.202108848,796.358,795.283047504,3.36,56,7,13,4,14,190.18,C39H42ClN11O4S,"InChI=1S/C39H42ClN11O4S/c1-22-23(2)56-39-35(22)36(26-6-10-27(40)11-7-26)44-31(37-48-46-24(3)51(37)39)18-33(53)43-19-29-21-50(49-47-29)17-5-4-16-41-34(54)20-42-28-12-8-25(9-13-28)30-14-15-32(52)45-38(30)55/h6-13,21,30-31,42H,4-5,14-20H2,1-3H3,(H,41,54)(H,43,53)(H,45,52,55)/t30?,31-/m0/s1",QRWLGRXLCZHZNC-FLDQDSGZSA-N
2897,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCCCCNC(=O)COC1=CC=C(C3CCC(=O)NC3=O)C=C1)N=C2C1=CC=C(Cl)C=C1,,,,,,8159,IC50 of BRD4 BD2 was assessed by TR-FRET,,,,,,,,,,,,,,,58,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.06/13.22,Inhibit proliferation of MV4-11/HD-MB03 cells,,,,,,,,,,,16.6,Compounds were administered at 10000 nM and incubated for 2 h,,,10.1002/anie.202108848,716.264,715.234365996,4.11,50,6,10,3,12,156.67,C36H38ClN7O5S,"InChI=1S/C36H38ClN7O5S/c1-20-21(2)50-36-32(20)33(24-6-10-25(37)11-7-24)40-28(34-43-42-22(3)44(34)36)18-30(46)38-16-4-5-17-39-31(47)19-49-26-12-8-23(9-13-26)27-14-15-29(45)41-35(27)48/h6-13,27-28H,4-5,14-19H2,1-3H3,(H,38,46)(H,39,47)(H,41,45,48)/t27?,28-/m0/s1",GBDCMEGOGDECAV-CPRJBALCSA-N
2898,O60885,BRD4,CRBN,,SJ995973,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCCCCCNC(=O)COC1=CC=C(C3CCC(=O)NC3=O)C=C1)N=C2C1=CC=C(Cl)C=C1,0.87/0.16,,Degradation of BRD4 in MV4-11 cells after 12/24 h treatment,,,3531,IC50 of BRD4 BD2 was assessed by TR-FRET,,,,,,,,,,,,,,,17,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.003,Inhibit proliferation of MV4-11 cells,,,,,,,,,,,14.3,Compounds were administered at 10000 nM and incubated for 2 h,,,10.1002/anie.202108848,730.291,729.25001606,4.47,51,6,10,3,13,156.67,C37H40ClN7O5S,"InChI=1S/C37H40ClN7O5S/c1-21-22(2)51-37-33(21)34(25-7-11-26(38)12-8-25)41-29(35-44-43-23(3)45(35)37)19-31(47)39-17-5-4-6-18-40-32(48)20-50-27-13-9-24(10-14-27)28-15-16-30(46)42-36(28)49/h7-14,28-29H,4-6,15-20H2,1-3H3,(H,39,47)(H,40,48)(H,42,46,49)/t28?,29-/m0/s1",VVRONDSUSMJAEI-XIJSCUBXSA-N
2899,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCCCCNC(=O)COC1=CC=CC(C3CCC(=O)NC3=O)=C1)N=C2C1=CC=C(Cl)C=C1,,,,,,2729,IC50 of BRD4 BD2 was assessed by TR-FRET,,,,,,,,,,,,,,,137,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,20.076/379.65,Inhibit proliferation of MV4-11/HD-MB03 cells,,,,,,,,,,,1,Compounds were administered at 10000 nM and incubated for 2 h,,,10.1002/anie.202108848,716.264,715.234365996,4.11,50,6,10,3,12,156.67,C36H38ClN7O5S,"InChI=1S/C36H38ClN7O5S/c1-20-21(2)50-36-32(20)33(23-9-11-25(37)12-10-23)40-28(34-43-42-22(3)44(34)36)18-30(46)38-15-4-5-16-39-31(47)19-49-26-8-6-7-24(17-26)27-13-14-29(45)41-35(27)48/h6-12,17,27-28H,4-5,13-16,18-19H2,1-3H3,(H,38,46)(H,39,47)(H,41,45,48)/t27?,28-/m0/s1",QGEJTBUIXFGTCP-CPRJBALCSA-N
2900,O60885,BRD4,CRBN,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCCCCCNC(=O)COC1=CC=CC(C3CCC(=O)NC3=O)=C1)N=C2C1=CC=C(Cl)C=C1,,,,,,2082,IC50 of BRD4 BD2 was assessed by TR-FRET,,,,,,,,,,,,,,,149,FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.147/64.85,Inhibit proliferation of MV4-11/HD-MB03 cells,,,,,,,,,,,9.7,Compounds were administered at 10000 nM and incubated for 2 h,,,10.1002/anie.202108848,730.291,729.25001606,4.47,51,6,10,3,13,156.67,C37H40ClN7O5S,"InChI=1S/C37H40ClN7O5S/c1-21-22(2)51-37-33(21)34(24-10-12-26(38)13-11-24)41-29(35-44-43-23(3)45(35)37)19-31(47)39-16-5-4-6-17-40-32(48)20-50-27-9-7-8-25(18-27)28-14-15-30(46)42-36(28)49/h7-13,18,28-29H,4-6,14-17,19-20H2,1-3H3,(H,39,47)(H,40,48)(H,42,46,49)/t28?,29-/m0/s1",MMTCVCBFVYDBKE-XIJSCUBXSA-N
3053,P10275,AR,CRBN,,ARD-1676,C[C@H]1CC2(CCN(C3=CC=C(C(=O)N4CCC(CN5CC6=CC7=C(C=C6C5)C(=O)N(C5CCC(=O)NC5=O)C7=O)CC4)C=C3)CC2)CN1C1=CC=C(C#N)C(Cl)=C1,0.1/1.1,99/98,Degradation of AR in VCaP/LNCaP cells after 24 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,11.5,Inhibit cell growth in the VCaP cells,,,,,,,,,,,0.07,permeability data in Caco-2 cells,0.13,permeability data in Caco-2 cells,10.1021/acs.jmedchem.3c01264,788.349,787.324895252,4.89,57,9,9,1,6,137.37,C44H46ClN7O5,"InChI=1S/C44H46ClN7O5/c1-27-21-44(26-51(27)34-7-4-30(22-46)37(45)20-34)12-16-49(17-13-44)33-5-2-29(3-6-33)41(55)50-14-10-28(11-15-50)23-48-24-31-18-35-36(19-32(31)25-48)43(57)52(42(35)56)38-8-9-39(53)47-40(38)54/h2-7,18-20,27-28,38H,8-17,21,23-26H2,1H3,(H,47,53,54)/t27-,38?/m0/s1",GAXWAKXJBZHVQF-ZVENJKCTSA-N
3120,Q00987,MDM2,MDM2,,,CCOC1=CC(C(C)(C)C)=CC=C1C1=NC(C2=CC=C(Cl)C=C2)C(C2=CC=C(Cl)C=C2)N1C(=O)N1CCN(CC(=O)NCCOCCOCCOCCNC(=O)CN2CCN(C(=O)N3C(C4=CC=C(C(C)(C)C)C=C4OCC)=NC(C4=CC=C(Cl)C=C4)C3C3=CC=C(Cl)C=C3)CC2=O)C(=O)C1,1010,>95,Degradation of MDM2 in A549 cells after 24 h treatment,,,,,,,,,100,MDM2-P53 competitive binding activities were tested by FP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1000/3300/1900,Inhibit proliferation of A549/HepG2/HCT116 cells,,,,,,,,,,,0.06,Compounds were administered at 10000 nM and incubated for 2 h,0.02,Compounds were administered at 10000 nM and incubated for 2 h,10.1016/j.apsb.2020.11.022,1459.411,1456.53881436,11.32,101,10,13,2,26,216.79,C76H88Cl4N10O11,"InChI=1S/C76H88Cl4N10O11/c1-9-100-61-43-53(75(3,4)5)19-29-59(61)71-83-67(49-11-21-55(77)22-12-49)69(51-15-25-57(79)26-16-51)89(71)73(95)87-35-33-85(65(93)47-87)45-63(91)81-31-37-97-39-41-99-42-40-98-38-32-82-64(92)46-86-34-36-88(48-66(86)94)74(96)90-70(52-17-27-58(80)28-18-52)68(50-13-23-56(78)24-14-50)84-72(90)60-30-20-54(76(6,7)8)44-62(60)101-10-2/h11-30,43-44,67-70H,9-10,31-42,45-48H2,1-8H3,(H,81,91)(H,82,92)",BYXQFJDQDXLTHH-UHFFFAOYSA-N
3148,P04035,HMGCR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCNC(=O)O[C@H]3C[C@@H](C)C=C4C=C[C@H](C)[C@H](CC[C@@H]5C[C@@H](O)CC(=O)O5)[C@H]43)C(C)(C)C)C=C2)SC=N1,,,,,,1320,Inhibition of HMGCR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,27.98,Caco-2 A2B assay,,,10.1016/j.apsb.2020.11.001,960.292,959.544200044,8.52,68,6,11,5,21,196.49,C53H77N5O9S,"InChI=1S/C53H77N5O9S/c1-33-25-38-19-16-34(2)42(23-22-41-27-39(59)29-46(62)66-41)47(38)44(26-33)67-52(65)54-24-14-12-10-8-7-9-11-13-15-45(61)57-49(53(4,5)6)51(64)58-31-40(60)28-43(58)50(63)55-30-36-17-20-37(21-18-36)48-35(3)56-32-68-48/h16-21,25,32-34,39-44,47,49,59-60H,7-15,22-24,26-31H2,1-6H3,(H,54,65)(H,55,63)(H,57,61)/t33-,34-,39+,40+,41+,42-,43-,44-,47-,49+/m0/s1",KDZGHUAZCDSHGD-XQKMAAOKSA-N
3149,P04035,HMGCR,VHL,,,CC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)CCCCCCCCCCNC(=O)O[C@H]3C[C@@H](C)C=C4C=C[C@H](C)[C@H](CCC(O)C[C@@H](O)CC(=O)O)[C@H]43)C(C)(C)C)C=C2)SC=N1,120,76,Degradation of HMGCR in HepG2 cells after 16 h treatment,,,250,Inhibition of HMGCR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,18.22,Caco-2 A2B assay,,,10.1016/j.apsb.2020.11.001,978.307,977.554764728,7.73,69,5,11,7,25,227.72,C53H79N5O10S,"InChI=1S/C53H79N5O10S/c1-33-25-38-19-16-34(2)42(23-22-39(59)27-40(60)29-46(63)64)47(38)44(26-33)68-52(67)54-24-14-12-10-8-7-9-11-13-15-45(62)57-49(53(4,5)6)51(66)58-31-41(61)28-43(58)50(65)55-30-36-17-20-37(21-18-36)48-35(3)56-32-69-48/h16-21,25,32-34,39-44,47,49,59-61H,7-15,22-24,26-31H2,1-6H3,(H,54,67)(H,55,65)(H,57,62)(H,63,64)/t33-,34-,39?,40+,41+,42-,43-,44-,47-,49+/m0/s1",YASBQIQZXTUKLR-SHAIEYSUSA-N
3443,Q06187,BTK,CRBN,,,NC1=NC=NC2=C1C(C1=CC=C(OC3=CC=CC=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)C2=CC=C(CNC3=CC=C4C(=O)N(C5CCC(=O)NC5=O)C(=O)C4=C3)C=C2)C1,,,,20.7/18.3,% BTK degradation in RAMOS cells after 24h treatment with 30/100 nM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.016,Compounds were administered at 10000 nM and incubated for 2 h,0.0099,Compounds were administered at 10000 nM and incubated for 2 h,10.1039/d3md00216k,775.826,775.286679904,4.32,58,9,12,3,9,194.74,C43H37N9O6,"InChI=1S/C43H37N9O6/c44-38-36-37(26-12-15-31(16-13-26)58-30-6-2-1-3-7-30)49-52(39(36)47-24-46-38)29-5-4-20-50(23-29)41(55)27-10-8-25(9-11-27)22-45-28-14-17-32-33(21-28)43(57)51(42(32)56)34-18-19-35(53)48-40(34)54/h1-3,6-17,21,24,29,34,45H,4-5,18-20,22-23H2,(H2,44,46,47)(H,48,53,54)/t29-,34?/m1/s1",TZIRXHQCCKGWER-QMUARQKKSA-N
4293,O60885,BRD4,VHL,,,CC1=C(C)C2=C(S1)N1C(C)=NN=C1[C@H](CC(=O)NCCCCCOC1=NOC([C@@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)C3=CC=C(Cl)C=C3)C(C)C)=C1)N=C2C1=CC=C(Cl)C=C1,190,80,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,187,ITC,,,,,,,,,,,,,,,,,,,,,,,0.05,Caco-2 A2B assay,16,Caco-2 B2A assay,10.1002/cmdc.202200615,903.934,902.310757744,7.03,62,7,12,3,16,177.07,C45H52Cl2N8O6S,"InChI=1S/C45H52Cl2N8O6S/c1-24(2)39(44(59)54-23-33(56)20-35(54)43(58)49-26(4)29-10-14-31(46)15-11-29)36-22-38(53-61-36)60-19-9-7-8-18-48-37(57)21-34-42-52-51-28(6)55(42)45-40(25(3)27(5)62-45)41(50-34)30-12-16-32(47)17-13-30/h10-17,22,24,26,33-35,39,56H,7-9,18-21,23H2,1-6H3,(H,48,57)(H,49,58)/t26-,33+,34-,35-,39-/m0/s1",MEHBZJQWERYZKL-VBKHBCKHSA-N
4295,O60885,BRD4,VHL,,,CC1=NOC([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](C)C2=CC=C(Cl)C=C2OCCOCCOCCOCCNC(=O)C[C@@H]2N=C(C3=CC=C(Cl)C=C3)C3=C(SC(C)=C3C)N3C(C)=NN=C23)C(C)C)=C1,210,89,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,33,ITC,,,,,,,,,,,,,,,,,,,,,,,0.07,Caco-2 A2B assay,20,Caco-2 B2A assay,10.1002/cmdc.202200615,1008.039,1006.35810186,5.58,69,7,15,3,22,204.76,C49H60Cl2N8O9S,"InChI=1S/C49H60Cl2N8O9S/c1-27(2)43(41-22-28(3)57-68-41)48(63)58-26-36(60)24-39(58)47(62)53-30(5)37-13-12-35(51)23-40(37)67-21-20-66-19-18-65-17-16-64-15-14-52-42(61)25-38-46-56-55-32(7)59(46)49-44(29(4)31(6)69-49)45(54-38)33-8-10-34(50)11-9-33/h8-13,22-23,27,30,36,38-39,43,60H,14-21,24-26H2,1-7H3,(H,52,61)(H,53,62)/t30-,36+,38-,39-,43+/m0/s1",QMDXZTNQRYGNEC-SKEOZXKHSA-N
4296,O60885,BRD4,VHL,,,CC1=NOC([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](C)C2=CC=C(C3=C(C)N=CS3)C=C2OCCOCCOCCOCCNC(=O)C[C@@H]2N=C(C3=CC=C(Cl)C=C3)C3=C(SC(C)=C3C)N3C(C)=NN=C23)C(C)C)=C1,16,82,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4,ITC,,,,,,,,,,,,,,,,,,,,,,,0.07,Caco-2 A2B assay,11,Caco-2 B2A assay,10.1002/cmdc.202200615,1070.736,1069.39569431,6.04,74,8,17,3,23,217.65,C53H64ClN9O9S2,"InChI=1S/C53H64ClN9O9S2/c1-29(2)46(44-23-30(3)61-72-44)52(67)62-27-39(64)25-42(62)51(66)57-32(5)40-14-11-37(49-33(6)56-28-73-49)24-43(40)71-22-21-70-20-19-69-18-17-68-16-15-55-45(65)26-41-50-60-59-35(8)63(50)53-47(31(4)34(7)74-53)48(58-41)36-9-12-38(54)13-10-36/h9-14,23-24,28-29,32,39,41-42,46,64H,15-22,25-27H2,1-8H3,(H,55,65)(H,57,66)/t32-,39+,41-,42-,46+/m0/s1",UIERTIMQQRRSTO-BEDMWFMASA-N
4297,O60885,BRD4,VHL,,,CC1=NOC([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC(=O)NCCCCNC(=O)C[C@@H]2N=C(C3=CC=C(Cl)C=C3)C3=C(SC(C)=C3C)N3C(C)=NN=C23)C2=CC=C(Cl)C=C2)C(C)C)=C1,190,80,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,63,ITC,,,,,,,,,,,,,,,,,,,,,,,0.06,Caco-2 A2B assay,7.5,Caco-2 B2A assay,10.1002/cmdc.202200615,930.96,929.321656776,5.65,64,7,12,4,16,196.94,C46H53Cl2N9O6S,"InChI=1S/C46H53Cl2N9O6S/c1-24(2)40(37-19-25(3)55-63-37)45(62)56-23-33(58)20-36(56)44(61)52-34(29-9-13-31(47)14-10-29)21-38(59)49-17-7-8-18-50-39(60)22-35-43-54-53-28(6)57(43)46-41(26(4)27(5)64-46)42(51-35)30-11-15-32(48)16-12-30/h9-16,19,24,33-36,40,58H,7-8,17-18,20-23H2,1-6H3,(H,49,59)(H,50,60)(H,52,61)/t33-,34+,35+,36+,40-/m1/s1",STGFOSWNXWQTTP-LADHRSEISA-N
4298,O60885,BRD4,VHL,,,CC1=NOC([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC(=O)NCCOCCOCCNC(=O)C[C@@H]2N=C(C3=CC=C(Cl)C=C3)C3=C(SC(C)=C3C)N3C(C)=NN=C23)C2=CC=C(Cl)C=C2)C(C)C)=C1,1500,100,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,64,ITC,,,,,,,,,,,,,,,,,,,,,,,0.06,Caco-2 A2B assay,6,Caco-2 B2A assay,10.1002/cmdc.202200615,991.012,989.342786144,4.64,68,7,14,4,20,215.4,C48H57Cl2N9O8S,"InChI=1S/C48H57Cl2N9O8S/c1-26(2)42(39-21-27(3)57-67-39)47(64)58-25-35(60)22-38(58)46(63)54-36(31-7-11-33(49)12-8-31)23-40(61)51-15-17-65-19-20-66-18-16-52-41(62)24-37-45-56-55-30(6)59(45)48-43(28(4)29(5)68-48)44(53-37)32-9-13-34(50)14-10-32/h7-14,21,26,35-38,42,60H,15-20,22-25H2,1-6H3,(H,51,61)(H,52,62)(H,54,63)/t35-,36+,37+,38+,42-/m1/s1",MIHQDVSIMCDUSP-PXYAPSQZSA-N
4299,O60885,BRD4,VHL,,,CC1=NOC([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC(=O)NCCOCCOCCOCCNC(=O)C[C@@H]2N=C(C3=CC=C(Cl)C=C3)C3=C(SC(C)=C3C)N3C(C)=NN=C23)C2=CC=C(Cl)C=C2)C(C)C)=C1,1100,100,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,43,ITC,,,,,,,,,,,,,,,,,,,,,,,0.04,Caco-2 A2B assay,5.5,Caco-2 B2A assay,10.1002/cmdc.202200615,1035.065,1033.36900089,4.49,71,7,15,4,23,224.63,C50H61Cl2N9O9S,"InChI=1S/C50H61Cl2N9O9S/c1-28(2)44(41-23-29(3)59-70-41)49(66)60-27-37(62)24-40(60)48(65)56-38(33-7-11-35(51)12-8-33)25-42(63)53-15-17-67-19-21-69-22-20-68-18-16-54-43(64)26-39-47-58-57-32(6)61(47)50-45(30(4)31(5)71-50)46(55-39)34-9-13-36(52)14-10-34/h7-14,23,28,37-40,44,62H,15-22,24-27H2,1-6H3,(H,53,63)(H,54,64)(H,56,65)/t37-,38+,39+,40+,44-/m1/s1",VPCHZAQARNLMRU-YLIPSVQPSA-N
4300,O60885,BRD4,VHL,,,CC1=NOC([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC(=O)NCCCCNC(=O)C[C@@H]2N=C(C3=CC=C(Cl)C=C3)C3=C(SC(C)=C3C)N3C(C)=NN=C23)C2=CC=C(C3=C(C)N=CS3)C=C2)C(C)C)=C1,320,94,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10,ITC,,,,,,,,,,,,,,,,,,,,,,,0.08,Caco-2 A2B assay,2,Caco-2 B2A assay,10.1002/cmdc.202200615,993.657,992.359249224,6.11,69,8,14,4,17,209.83,C50H57ClN10O6S2,"InChI=1S/C50H57ClN10O6S2/c1-26(2)43(40-20-27(3)59-67-40)49(66)60-24-36(62)21-39(60)48(65)56-37(32-10-12-34(13-11-32)46-29(5)54-25-68-46)22-41(63)52-18-8-9-19-53-42(64)23-38-47-58-57-31(7)61(47)50-44(28(4)30(6)69-50)45(55-38)33-14-16-35(51)17-15-33/h10-17,20,25-26,36-39,43,62H,8-9,18-19,21-24H2,1-7H3,(H,52,63)(H,53,64)(H,56,65)/t36-,37+,38+,39+,43-/m1/s1",KRPIEYYWXMOWMP-CFAWEHKJSA-N
4301,O60885,BRD4,VHL,,,CC1=NOC([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC(=O)NCCOCCOCCNC(=O)C[C@@H]2N=C(C3=CC=C(Cl)C=C3)C3=C(SC(C)=C3C)N3C(C)=NN=C23)C2=CC=C(C3=C(C)N=CS3)C=C2)C(C)C)=C1,570,79,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,14,ITC,,,,,,,,,,,,,,,,,,,,,,,0.07,Caco-2 A2B assay,2.2,Caco-2 B2A assay,10.1002/cmdc.202200615,1053.709,1052.38037859,5.1,73,8,16,4,21,228.29,C52H61ClN10O8S2,"InChI=1S/C52H61ClN10O8S2/c1-28(2)45(42-22-29(3)61-71-42)51(68)62-26-38(64)23-41(62)50(67)58-39(34-8-10-36(11-9-34)48-31(5)56-27-72-48)24-43(65)54-16-18-69-20-21-70-19-17-55-44(66)25-40-49-60-59-33(7)63(49)52-46(30(4)32(6)73-52)47(57-40)35-12-14-37(53)15-13-35/h8-15,22,27-28,38-41,45,64H,16-21,23-26H2,1-7H3,(H,54,65)(H,55,66)(H,58,67)/t38-,39+,40+,41+,45-/m1/s1",PMMBPUFPJGYZDS-NNYWTZBRSA-N
4302,O60885,BRD4,VHL,,,CC1=NOC([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC(=O)NCCOCCOCCOCCNC(=O)C[C@@H]2N=C(C3=CC=C(Cl)C=C3)C3=C(SC(C)=C3C)N3C(C)=NN=C23)C2=CC=C(C3=C(C)N=CS3)C=C2)C(C)C)=C1,560,93,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6,ITC,,,,,,,,,,,,,,,,,,,,,,,0.08,Caco-2 A2B assay,1.8,Caco-2 B2A assay,10.1002/cmdc.202200615,1097.762,1096.40659334,4.95,76,8,17,4,24,237.52,C54H65ClN10O9S2,"InChI=1S/C54H65ClN10O9S2/c1-30(2)47(44-24-31(3)63-74-44)53(70)64-28-40(66)25-43(64)52(69)60-41(36-8-10-38(11-9-36)50-33(5)58-29-75-50)26-45(67)56-16-18-71-20-22-73-23-21-72-19-17-57-46(68)27-42-51-62-61-35(7)65(51)54-48(32(4)34(6)76-54)49(59-42)37-12-14-39(55)15-13-37/h8-15,24,29-30,40-43,47,66H,16-23,25-28H2,1-7H3,(H,56,67)(H,57,68)(H,60,69)/t40-,41+,42+,43+,47-/m1/s1",COKARWVIPXUBBF-RBFTVJCPSA-N
4303,O60885,BRD4,VHL,,,CC1=NOC([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](C)C2=CC=C(C3=C(C#CCOCCOCCOCCNC(=O)C[C@@H]4N=C(C5=CC=C(Cl)C=C5)C5=C(SC(C)=C5C)N5C(C)=NN=C45)N=CS3)C=C2)C(C)C)=C1,16,98,Degradation of BRD4 in A549 cells after 4h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8,ITC,,,,,,,,,,,,,,,,,,,,,,,0.06,Caco-2 A2B assay,8.9,Caco-2 B2A assay,10.1002/cmdc.202200615,1050.705,1049.36947956,5.9,73,8,16,3,20,208.42,C53H60ClN9O8S2,"InChI=1S/C53H60ClN9O8S2/c1-30(2)46(44-25-31(3)61-71-44)52(67)62-28-40(64)26-43(62)51(66)57-33(5)36-10-12-38(13-11-36)49-41(56-29-72-49)9-8-19-68-21-23-70-24-22-69-20-18-55-45(65)27-42-50-60-59-35(7)63(50)53-47(32(4)34(6)73-53)48(58-42)37-14-16-39(54)17-15-37/h10-17,25,29-30,33,40,42-43,46,64H,18-24,26-28H2,1-7H3,(H,55,65)(H,57,66)/t33-,40+,42-,43-,46+/m0/s1",WUYXNOSTUQQLBT-RXJHFLANSA-N
4355,P42229,STAT5,CRBN,,AK-2292,CN(CCCC#CC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)C(=O)CCN(C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)C1=CC2=CC(C(F)(F)P(=O)(O)O)=CC=C2S1)C(C)(C)C)C1=CC=C(C2=NC=CS2)C=C1,160/200,95/95,Degradation of STAT5 in KU812/PBMC cells after 18h treatment,,,,,,,,,500,Binding affinity of STAT5A,,,,,,,,,,,,,,,170.0,Binding affinity of CRBN,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.06,Caco-2 A2B assay,0.09,Caco-2 B2A assay,10.1038/s41589-022-01248-4,1070.147,1069.307926,5.25,74,8,11,4,15,226.93,C52H54F2N7O10PS2,"InChI=1S/C52H54F2N7O10PS2/c1-51(2,3)44(57-46(65)41-29-33-28-34(16-20-40(33)74-41)52(53,54)72(69,70)71)50(68)60-25-9-13-39(60)49(67)59(35-17-14-32(15-18-35)47-55-23-27-73-47)26-22-43(63)58(4)24-7-5-6-10-31-11-8-12-36-37(31)30-61(48(36)66)38-19-21-42(62)56-45(38)64/h8,11-12,14-18,20,23,27-29,38-39,44H,5,7,9,13,19,21-22,24-26,30H2,1-4H3,(H,57,65)(H,56,62,64)(H2,69,70,71)/t38?,39-,44+/m0/s1",LOPYPDQOHNOVBM-QOIUHGAOSA-N
4934,,BCR-ABL,CRBN,,SIAIS100,O=C1CCC(N2CC3=C(SCCCCCCN4CCN(C5CCN(C6=NC=C(C(=O)NC7=CC=C(OC(F)(F)Cl)C=C7)C=C6C6=CC=N[NH]6)CC5)CC4)C=CC=C3C2=O)C(=O)N1,2.7,91.2,Degradation of BCR-ABL in K562 cells after 16h treatment,81.78/91.20,% BCR-ABL protein degradation in K562 cells at 5/100 nM,,,,,4740,Binding affinity with ABL recombinant protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12,Inhibition of cell proliferation of K562 cells,,,,,,,,,,,0.11,Permeation of the test compounds from A to B direction in Coca-2 was determined,1.03,Permeation of the test compounds from B to A direction in Coca-2 was determined,10.1016/j.ejmech.2022.114810,890.458,889.33122082,5.82,62,8,11,3,16,156.1,C44H50ClF2N9O5S,"InChI=1S/C44H50ClF2N9O5S/c45-44(46,47)61-32-10-8-30(9-11-32)50-41(58)29-26-34(36-14-17-49-52-36)40(48-27-29)55-19-15-31(16-20-55)54-23-21-53(22-24-54)18-3-1-2-4-25-62-38-7-5-6-33-35(38)28-56(43(33)60)37-12-13-39(57)51-42(37)59/h5-11,14,17,26-27,31,37H,1-4,12-13,15-16,18-25,28H2,(H,49,52)(H,50,58)(H,51,57,59)",QRGISIMVAZWDHL-UHFFFAOYSA-N
5215,Q5S007,LRRK2,VHL,,,CNC1=NC(NC2=CC=C(C(=O)N3CCN(C[C@H]4CC[C@H](CSC(C)(C)[C@H](NC(=O)C5(F)CC5)C(=O)N5C[C@H](O)C[C@H]5C(=O)NCC5=CC=C(C6=C(C)N=CS6)C=C5)CC4)CC3)C=C2OC)=NC=C1Cl,32,82,Degradation of LRRK2 in MEFs after 4 h treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,54,Dephosphorylation of Rab10 in WT LRRK2 MEFs,,,,,,,,,0.74,Caco-2 permeability,1.43,Caco-2 permeability,10.1021/jacs.2c05499,1019.711,1018.41242767,6.33,70,8,14,5,18,194.25,C50H64ClFN10O6S2,"InChI=1S/C50H64ClFN10O6S2/c1-30-41(69-29-56-30)34-12-10-31(11-13-34)24-54-44(64)39-23-36(63)27-62(39)46(66)42(58-47(67)50(52)16-17-50)49(2,3)70-28-33-8-6-32(7-9-33)26-60-18-20-61(21-19-60)45(65)35-14-15-38(40(22-35)68-5)57-48-55-25-37(51)43(53-4)59-48/h10-15,22,25,29,32-33,36,39,42,63H,6-9,16-21,23-24,26-28H2,1-5H3,(H,54,64)(H,58,67)(H2,53,55,57,59)/t32-,33-,36-,39+,42-/m1/s1",HKSBXNVKPFTBIG-SHFRUIRLSA-N
5233,Q05397,FAK,CRBN,,,CN(C1=CC=CC=C1CNC1=NC(NC2=CC=C(N3CCN(CCCCCCC(=O)NCCNC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)C=C2)=NC=C1C(F)(F)F)S(C)(=O)=O,,,,,,26.4,Inhibit of FAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,<0.48,Caco-2 permeability,0.417,Caco-2 permeability,10.1080/14756366.2022.2100886,962.069,961.388048728,5.15,68,7,14,5,20,218.38,C46H54F3N11O7S,"InChI=1S/C46H54F3N11O7S/c1-57(68(2,66)67)36-13-7-6-10-30(36)28-52-41-34(46(47,48)49)29-53-45(56-41)54-31-15-17-32(18-16-31)59-26-24-58(25-27-59)23-8-4-3-5-14-38(61)51-22-21-50-35-12-9-11-33-40(35)44(65)60(43(33)64)37-19-20-39(62)55-42(37)63/h6-7,9-13,15-18,29,37,50H,3-5,8,14,19-28H2,1-2H3,(H,51,61)(H,55,62,63)(H2,52,53,54,56)",NYOWKFWVZFPCFY-UHFFFAOYSA-N
5640,Q05397,FAK,CRBN,,,CNC(=O)C1=CC=CC=C1NC1=NC(NC2=CC=C(N3CCN(CCCCC(=O)NC4=CC=CC5=C4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)C=C2OC)=NC=C1Cl,,,,92.4/86.4,% FAK degradation in A549 cells at 100/10 nM,14.9,Binding affinity to FAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,140,Inhibit cell proliferation of A549 cells,,,,,,,,,,,1.4,A-B permeability,4.7,B-A permeability,10.1016/j.ejmech.2022.114373,823.311,822.300471396,4.59,59,7,13,5,14,207.3,C41H43ClN10O7,"InChI=1S/C41H43ClN10O7/c1-43-37(55)25-8-3-4-10-28(25)46-36-27(42)23-44-41(49-36)47-29-14-13-24(22-32(29)59-2)51-20-18-50(19-21-51)17-6-5-12-33(53)45-30-11-7-9-26-35(30)40(58)52(39(26)57)31-15-16-34(54)48-38(31)56/h3-4,7-11,13-14,22-23,31H,5-6,12,15-21H2,1-2H3,(H,43,55)(H,45,53)(H,48,54,56)(H2,44,46,47,49)",WGXCHVXCUMEKET-UHFFFAOYSA-N
